Spread the love“`html 1. The Fascination with 2D Games 2D games have captured the hearts of gamers and developers alike for decades. From classic titles like Super Mario Bros. to modern indie hits ...
Abstract: Dyslexia is a complex reading disorder characterized by difficulties in accurate or fluent word recognition, poor spelling, and decoding abilities. These challenges are not due to ...
Abstract: Alzheimer's Disease (AD) is a prevalent neurodegenerative condition where early detection is vital. Handwriting, often affected early in AD, offers a non-invasive and cost-effective way to ...
A turn-based HD-2D Final Fantasy, huh. It’s hard to believe it’s real. As someone who grew up on old-school Final Fantasy games and JRPGs, it's also hard to believe I was able to play Final Fantasy ...
As part of the June 2026 Nintendo Direct, Square Enix revealed Final Fantasy Resonance, an HD-2D turn-based RPG that's set to release on October 22 this year for PlayStation, Xbox, PC, and Nintendo ...
Final Fantasy Resonance was revealed during today's Nintendo Direct, and brings the HD-2D art style, popularized by the Octopath Traveler games, to Square Enix's flagship franchise. The game comes out ...
Square Enix has revealed Final Fantasy Resonance, a new entry in the series that boasts HD-2D visuals and turn-based battles. Characters from other entries will also make appearances, including Cloud ...
🎉 2026-02-14 · v0.1.3 Released. The v0.1.3 release introduces full support for the latest GLM-5 model, achieving up to 500 tokens/s on GLM-5-FP8 and up to 600 tokens/s on DeepSeek-V3.2. TileRT is a ...
Our AI models have generated three distinct trading strategies tailored to different risk profiles and holding periods. Each strategy incorporates sophisticated risk management parameters designed to ...
FRIDAY, June 5, 2026 (HealthDay News) -- For patients with newly diagnosed resectable brain metastases (BM), cesium-131 tile-based radiation therapy (TBRT), which delivers focal radiation immediately ...
Low-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results